News
Public · Published
Piper Sandler maintains Corcept Therapeutics at Overweight, raises price target to $173 from $165
Piper Sandler maintained its Overweight rating on Corcept Therapeutics and raised its price target to $173 from $165. The new target is a 4.8% increase and implies 111.2% upside from the November 3 closing price of $81.93.
Published:
Updated:
What happened
Piper Sandler maintained its Overweight rating on Corcept Therapeutics and raised its price target to $173 from $165. The new target is a 4.8% increase and implies 111.2% upside from the November 3 closing price of $81.93.
Confirmed
Global impact / market context
The higher target signals that Piper Sandler sees more potential value in Corcept shares than before, which may shape investor expectations and buying or selling decisions. However, a broker’s target is an estimate, not a guarantee that the share price will reach it.
Analyst inference
This is an analyst-rating update, not a company announcement about sales, costs, or business plans. The article gives no new operating results or explanation for the higher target, so it does not establish a change in Corcept’s underlying business prospects.
Analyst inference
What to watch
- Watch for future Piper Sandler changes to its rating or target, which would show whether the analyst continues to revise expectations for Corcept shares. Analyst inference
- Compare future company results and business updates with the assumptions behind the higher target; the article does not state what assumptions drove the increase. Analyst inference
- The stated 111.2% upside uses the November 3 close of $81.93 as its reference point, so later share prices would change the implied upside. Confirmed
Evidence
- Original source link unavailable